EGFR and non-small cell lung carcinoma: As our previous results demonstrated that EHMT2 expression and activity levels were increased in EGFR-TKI-resistant NSCLC cells (Fig. 2a), we performed additional investigations to confirm whether ablation of EHMT2 expression could sensitize resistant NSCLC cells to TKI in vivo.